Belgian biotech Cannovex and Dutch DPI developer PureIMS announced that Cannovex has acquired exclusive rights to develop pharmaceutical cannabinoid products delivered via PureIMS’s Cyclops high-dose dry powder inhaler. The companies say that they have entered into a strategic partnership for development of Cannovex DPI formulations delivered via the Cyclops device, with the initiation of a Phase 1 trial expected in 2027. According to the Cannovex web site, Cannovex’s pipeline includes the CNX-THC DPI, which is in IND-enabling studies, and the CNX-CBD DPI, which is in pre-clinical development.
PureIMS has a pipeline of its own formulations delivered via the Cyclops DPI, including Colistin Cyclops for the treatment of P. aeruginosa infections in cystic fibrosis and bronchiectasis patients, Levodopa Cyclops for the treatment of OFF episodes in Parkinson’s disease, and Amikacin Cyclops for the treatment of tuberculosis and NTM lung infections.
Cannovex CEO Steven Peters commented, “With growing scientific evidence supporting the therapeutic potential of cannabinoids, inhalation offers a patient-friendly and highly effective delivery route. Our formulations are specifically designed for the Cyclops platform to enable consistent systemic exposure across a range of potential therapeutic applications. This partnership provides a strong technological foundation for reproducible dosing, and scalable pharmaceutical-grade manufacturing.”
PureIMS CEO Jaap Wieling said, “This collaboration is a significant milestone for PureIMS and validates the versatility of our Cyclops platform. Cannovex’ commitment to rigorous science and pharmaceutical quality aligns perfectly with our own standards. By moving away from the inconsistent approaches of the past, we are ensuring that patients receive the maximum therapeutic benefit from these innovative products.”
Read the Cannovex and PureIMS press release
